Review



anti il 34 antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems anti il 34 antibody
    ( A ) Experimental design employed to evaluate the therapeutic <t>efficacy</t> <t>of</t> <t>anti–IL-34</t> antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.
    Anti Il 34 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+il+34+antibody/pmc13132371-273-8-12?v=R%26D+Systems
    Average 93 stars, based on 10 article reviews
    anti il 34 antibody - by Bioz Stars, 2026-08
    93/100 stars

    Images

    1) Product Images from "A CD138 + tumor-associated macrophage/Siglec-F + neutrophil feed-forward loop promotes immune evasion in pancreatic cancer"

    Article Title: A CD138 + tumor-associated macrophage/Siglec-F + neutrophil feed-forward loop promotes immune evasion in pancreatic cancer

    Journal: The Journal of Clinical Investigation

    doi: 10.1172/JCI199516

    ( A ) Experimental design employed to evaluate the therapeutic efficacy of anti–IL-34 antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.
    Figure Legend Snippet: ( A ) Experimental design employed to evaluate the therapeutic efficacy of anti–IL-34 antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.

    Techniques Used: Drug discovery, Flow Cytometry, Comparison



    Similar Products

    il  (Bioss)
    94
    Bioss il
    Il, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+il+34+antibody/pmc11781702-42-49-59?v=Bioss
    Average 94 stars, based on 1 article reviews
    il - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    anti il 34 antibody  (R&D Systems)
    93
    R&D Systems anti il 34 antibody
    ( A ) Experimental design employed to evaluate the therapeutic <t>efficacy</t> <t>of</t> <t>anti–IL-34</t> antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.
    Anti Il 34 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+il+34+antibody/pmc13132371-273-8-12?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    anti il 34 antibody - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    anti il 34  (Boster Bio)
    94
    Boster Bio anti il 34
    ( A ) Experimental design employed to evaluate the therapeutic <t>efficacy</t> <t>of</t> <t>anti–IL-34</t> antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.
    Anti Il 34, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+il+34+antibody/pmc12990819-67-15-16?v=Boster+Bio
    Average 94 stars, based on 1 article reviews
    anti il 34 - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    il34  (R&D Systems)
    93
    R&D Systems il34
    ( A ) Experimental design employed to evaluate the therapeutic <t>efficacy</t> <t>of</t> <t>anti–IL-34</t> antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.
    Il34, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+il+34+antibody/pm40907490-576-17-18?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    il34 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    il 34  (R&D Systems)
    93
    R&D Systems il 34
    ( A ) Experimental design employed to evaluate the therapeutic <t>efficacy</t> <t>of</t> <t>anti–IL-34</t> antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.
    Il 34, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+il+34+antibody/pm40169980-87-0-1?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    il 34 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    human anti il 34  (R&D Systems)
    93
    R&D Systems human anti il 34
    ( A ) Experimental design employed to evaluate the therapeutic <t>efficacy</t> <t>of</t> <t>anti–IL-34</t> antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.
    Human Anti Il 34, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+il+34+antibody/pm40101804-46-6-43?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    human anti il 34 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    rabbit  (Boster Bio)
    94
    Boster Bio rabbit
    ( A ) Experimental design employed to evaluate the therapeutic <t>efficacy</t> <t>of</t> <t>anti–IL-34</t> antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.
    Rabbit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+il+34+antibody/pm39864284-94-20-26?v=Boster+Bio
    Average 94 stars, based on 1 article reviews
    rabbit - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Experimental design employed to evaluate the therapeutic efficacy of anti–IL-34 antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.

    Journal: The Journal of Clinical Investigation

    Article Title: A CD138 + tumor-associated macrophage/Siglec-F + neutrophil feed-forward loop promotes immune evasion in pancreatic cancer

    doi: 10.1172/JCI199516

    Figure Lengend Snippet: ( A ) Experimental design employed to evaluate the therapeutic efficacy of anti–IL-34 antibodies in conjunction with anti–PD-1 antibodies in PDAC. ( B ) Quantification of tumor weight ( n = 8 per group). ( C and D ) Quantification of Ki67 + cell counts ( C ) and the percentage of CC3 + area ( D ) per ×40 field in tumor sections ( n = 8 per group). ( E ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. ( F and I ) Flow cytometry images showing CD138 + F4/80 + ( F ) and SAA3 + CXCL1 + ( I ) macrophages in the tumor tissues of mice following anti–IL-34 antibody treatment. ( G and H ) Quantification of data from F ( n = 6 per group). ( J and K ) Quantification of data from I ( n = 6 per group). ( L ) Representative plots illustrating the presence of Siglec-F + neutrophils in the tumor tissues of mice upon treatment with anti–IL-34 antibodies. ( M and N ) Quantification of data from L ( n = 6 per group). ( O ) Quantification of the frequencies of effector cell subsets among CD45 + cells in tumor tissues ( n = 6 per group). ( P and R ) Representative images depicting CD44 + CD62L – effector ( P ) and TIM3 + SLAMF6 – PD-1 + late-exhausted ( R ) CD8 + T cells within the tumor tissues. ( Q ) Quantification of data from P ( n = 6 per group). ( S ) Quantification of data from R ( n = 6 per group). ( T ) Overall survival probabilities of mice ( n = 8 per group). The dashed line indicates the time point when the combination therapy commenced. * P < 0.05, ** P < 0.01, and *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple-comparison test ( B – D , O , Q , and S ), by log-rank analysis ( E and T ), and by unpaired 2-tailed Student’s t test ( G , H , J , K , M , and N ). Data represent mean ± SEM.

    Article Snippet: Mice were intraperitoneally injected with 200 μg of anti–IL-34 antibody (catalog MAB5195, R&D Systems) every other day, totaling 6 doses, starting on day 9 after the orthotopic inoculation of 5 × 10 5 KPC cells.

    Techniques: Drug discovery, Flow Cytometry, Comparison